Prevention of restenosis with antioxidants: mechanisms and implications - PubMed (original) (raw)
Review
Prevention of restenosis with antioxidants: mechanisms and implications
Jean-Claude Tardif et al. Am J Cardiovasc Drugs. 2002.
Abstract
The aim of this review is to give an overview of the field of restenosis prevention with antioxidants, put in the perspective of their potential use for the prevention of atherosclerosis progression. Compelling evidence points to oxidative stress as an important trigger in the complex chain of events leading to atherosclerosis. There is also evidence that oxidative stress occurs early after angioplasty. Reactive oxygen species (ROS) can induce endothelial dysfunction and macrophage activation, resulting in the release of cytokines and growth factors that stimulate matrix remodeling and smooth muscle cell proliferation. The accumulation of new extracellular matrix and smooth muscle cells will result in the neointimal formation responsible for lumen narrowing after stent deployment and which contributes to that after balloon angioplasty. In addition, oxidation processes are involved in the cross-linking of collagen fibers, and this coupled with smooth muscle cell contraction and endothelial dysfunction may result in long-term vascular constriction or lack of adaptive vascular remodeling after balloon angioplasty. The powerful antioxidant probucol has been shown to prevent coronary restenosis after balloon angioplasty in the Multivitamins and Probucol (MVP) trial and other clinical studies. However, prolongation of the QT interval with probucol remains a long-term safety concern. AGI-1067, a metabolically stable analog of probucol, is a vascular protectant with strong antioxidant properties as potent to those of probucol. There has been no evidence of prolongation of the QT interval with AGI-1067 in initial clinical studies. The anti-restenosis properties of AGI-1067 are being assessed in the Canadian Antioxidant Restenosis Trial (CART)-1. Considering that oxidative stress and inflammation may persist for a prolonged period after stent placement, treatment with AGI-1067 for the entire period of risk after percutaneous coronary intervention (PCI) [instead of only 4 weeks in CART-1] may result in enhanced protection against luminal renarrowing. This hypothesis will be tested in the randomized, multicenter CART-2 trial. AGI-1067 has been effective at preventing atherosclerosis in all tested animal models, including the low density lipoprotein receptor-deficient and apo-E knockout mice. This has potentially important implications, as PCI and local approaches to prevent restenosis such as coated stents are not expected to prevent atherosclerosis progression, myocardial infarction and cardiovascular death. As the ultimate goal of therapy for patients with coronary artery disease must remain prevention of disease progression and atherosclerosis-related events, CART-2 will test the value of AGI-1067 for the reduction of both post-PCI restenosis and atherosclerosis progression.
Similar articles
- Clinical results with AGI-1067: a novel antioxidant vascular protectant.
Tardif JC. Tardif JC. Am J Cardiol. 2003 Feb 6;91(3A):41A-49A. doi: 10.1016/s0002-9149(02)03149-1. Am J Cardiol. 2003. PMID: 12645643 Review. - Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
Tardif JC, Grégoire J, Lavoie MA, L'Allier PL. Tardif JC, et al. Curr Opin Lipidol. 2003 Dec;14(6):615-20. doi: 10.1097/00041433-200312000-00010. Curr Opin Lipidol. 2003. PMID: 14624139 Review. - Antioxidants: the good, the bad and the ugly.
Tardif JC. Tardif JC. Can J Cardiol. 2006 Feb;22 Suppl B(Suppl B):61B-65B. doi: 10.1016/s0828-282x(06)70988-6. Can J Cardiol. 2006. PMID: 16498514 Free PMC article. Review. - Antioxidants and atherosclerosis: emerging drug therapies.
Tardif JC. Tardif JC. Curr Atheroscler Rep. 2005 Feb;7(1):71-7. doi: 10.1007/s11883-005-0078-1. Curr Atheroscler Rep. 2005. PMID: 15683606 Review. - Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Tardif JC, Grégoire J, Schwartz L, Title L, Laramée L, Reeves F, Lespérance J, Bourassa MG, L'Allier PL, Glass M, Lambert J, Guertin MC; Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Tardif JC, et al. Circulation. 2003 Feb 4;107(4):552-8. doi: 10.1161/01.cir.0000047525.58618.3c. Circulation. 2003. PMID: 12566365 Clinical Trial.
Cited by
- Association between Oxidative Burden and Restenosis: A Case-Control Study.
Ganjali S, Mansouri A, Abbasifard M, Moallem SA, Tayarani-Najaran Z, Sahebkar A. Ganjali S, et al. Oxid Med Cell Longev. 2022 Jun 28;2022:3577761. doi: 10.1155/2022/3577761. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35799893 Free PMC article. Retracted. - Oligoproline-derived nanocarrier for dual stimuli-responsive gene delivery.
Gupta MK , Lee SH , Crowder SW , Wang X , Hofmeister LH , Nelson CE , Bellan LM , Duvall CL , Sung HJ . Gupta MK , et al. J Mater Chem B. 2015 Sep 28;3(36):7271-7280. doi: 10.1039/c5tb00988j. Epub 2015 Aug 20. J Mater Chem B. 2015. PMID: 32262835 Free PMC article. - Protective effect of a hydrogen sulfide donor on balloon injury-induced restenosis via the Nrf2/HIF-1α signaling pathway.
Ling K, Xu A, Chen Y, Chen X, Li Y, Wang W. Ling K, et al. Int J Mol Med. 2019 Mar;43(3):1299-1310. doi: 10.3892/ijmm.2019.4076. Epub 2019 Jan 23. Int J Mol Med. 2019. PMID: 30747216 Free PMC article. - Linagliptin protects rat carotid artery from balloon injury and activates the NRF2 antioxidant pathway.
Si J, Meng R, Gao P, Hui F, Li Y, Liu X, Yang B. Si J, et al. Exp Anim. 2019 Feb 26;68(1):81-90. doi: 10.1538/expanim.18-0089. Epub 2018 Oct 23. Exp Anim. 2019. PMID: 30369549 Free PMC article. - Design, Synthesis, and In Vitro Evaluation of a Novel Probucol Derivative: Protective Activity in Neuronal Cells Through GPx Upregulation.
Quispe RL, Canto RFS, Jaramillo ML, Barbosa FAR, Braga AL, de Bem AF, Farina M. Quispe RL, et al. Mol Neurobiol. 2018 Oct;55(10):7619-7634. doi: 10.1007/s12035-018-0939-6. Epub 2018 Feb 12. Mol Neurobiol. 2018. PMID: 29430618
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous